IMPACT OF CIED INFECTIONS TYRX Absorbable Antibacterial Envelope

Consequences of Implantable Cardiac Device Infection on Patients and the Healthcare System

Despite efforts to take pacemaker precautions and reduce pacemaker risks, infection after cardiac implantable electronic defibrillators (CIEDs) implantation is a real possibility. When pacemaker infection does occur, the risk to the patient and the costs to the healthcare system are substantial.1-3

Infections typically cost the facility an average of ~$52,0004 but may exceed well over $100,000.3


CIED INFECTION AND MORTALITY

Mortality significantly increased following CIED infections. Studies show a ~50% mortality rate at three years in patients who had a CIED infection.1


CIED Infections Are Costly

An infection may cost a facility $52,000 on average, but may exceed $100,000 depending on the infection’s severity.

CIED infection rates affect Centers for Medicaid and Medicare Services (CMS) reimbursement.4 As of October 1, 2012, the CMS has reduced payments to hospitals when a patient undergoing a CIED procedure acquires an infection during their hospital stay.4


BENEFITS OF TYRX ANTIBACTERIAL ENVELOPES

The TYRX™ Absorbable Antibacterial Envelope may help reduce infection; studies show a 70% to 100% reduction of infection in high-risk patients.

Economic Impact of CIED Infection

A clinical and economic analysis (U.S. data) shows the projected savings of utilizing the TYRX Absorbable Antibacterial Envelope per patient.

1

Mittal S et al. Heart Rhythm. 2014;11(4):595-601.

2

Henrikson CA et al. JACC EP.2017;3(10):1158-1167.

3

Sohail MR et al. Arch Intern Med. 2011;171(20):1821-1828.

4

Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY13.